Waltham, Massachusetts based NeuroMetrix, Inc. unveiled and demonstrated its novel “Quell” wearable pain relief device at the 2015 International Consumer Electronics show (CES) this week in Las Vegas. NeuroMetrix was also chosen for inclusion in an exclusive group participating in CES Unveiled, the official CES press event, and the company’s Shai N. Gozani, M.D., Ph.D., was interviewed in the Digital Health LIVE CES WebMD Lounge. A video of the interview can be viewed here.
The technology used in Quell utilizes NeuroMetrix’s proprietary non-invasive neurostimulation technique aimed at providing relief from chronic pain, such as due to diabetes, sciatica, fibromyalgia, and degenerative knee function. The lightweight, advanced, wearable pain relief device is designed to be on call 24 hours a day, worn during daytime activities as well as in bed at night. It is claimed to automatically track sleep quality and automatically adjust to ensure the relief you need to sleep soundly.
Quell has been cleared by the FDA for chronic pain management and treatment without a prescription, and users will also have the option of using their smartphone to automatically track and personalize their Quell-based pain therapy.
The company claims that users will experience relief in as little as 15 minutes, and that Quell technology works with the wearer’s own body by both stimulating nerves and by blocking pain signals to the brain. Consumers and medical professionals can learn more and sign up to receive information at:
http://QuellRelief.com.
NeuroMetrix expects to begin taking pre-orders for Quell in March for shipment beginning during the second quarter of 2015. The Quell device will initially be available exclusively through doctors’ offices and online.
Quell was selected as one of four finalists in the Engadget Best of CES 2015 Digital Health and Fitness category. See: http://www.engadget.com/2015/01/07/introducing-the-best-of-ces-2015-finalists/; and C|NET profiled Quell in their CES2015 center. You can find the segment at: http://www.cnet.com/videos/quell-offers-wearable-pain-relief-without-medication/
The Company also reported this week that Shai N. Gozani, M.D. , Ph.D., President and Chief Executive Officer would participate in a CES Digital Health Summit panel entitled “Winning the War on Diabetes” a panel discussion that was held January 8.
Dr. Gozani comments: “Recent studies have shown that chronic nerve pain dramatically reduces the quality of life of people with diabetes. We believe that Quell may help many of these people reclaim their life from chronic pain.”
Dr. Gozani is the author of more than 30 peer-reviewed scientific articles and has been awarded 25 US and international patents. He holds a B.A. degree in Computer Science, an M.S. degree in Electrical Engineering and Computer Science (Biomedical Engineering Focus) and a Ph.D. in Neurobiology, from the University of California, Berkeley. Dr. Gozani also received his M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at M.I.T. For more information, visit: http://www.neurometrix.com/about-neurometrix/board-of-directors.html#sthash.rWiOxSCG.dpuf
NeuroMetrix, Inc. was founded by Dr. Gozani in 1996 as a Massachusetts Institute of Technology spin-off. Currently serving as Chairman of the board of directors and as NeuroMatrix’s President and CEO, Dr. Gozani has led the company from a venture capital backed start-up, through an initial public offering on Nasdaq, through development of a successful diagnostics busine
ss, and presently into the wearable technology sector. NeuroMetrix says more than 2.5 million patients have benefited from its technologies over the past 15 years.
In addition to Dr. Gozani, NeuroMetrix has been represented at CES by Frank McGillin, SVP and General Manager Consumer, as well as members of the company’s product development and marketing teams.
For more information about NeuroMetrix, visit:
http://www.NeuroMetrix.com
Sources:
NeuroMetrix
Image Credits:
NeuroMetrix